NCT04464525View on ClinicalTrials.gov

Omecamtiv Mecarbil Post-trial Access Study

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 18, 2020

Primary Completion Date

November 27, 2026

Study Completion Date

November 27, 2026

Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

Omecamtiv mecarbil

Film-coated tablet administered orally.

Sponsors

Lead Sponsor

Cytokinetics
All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT04464525 - Omecamtiv Mecarbil Post-trial Access Study | Biotech Hunter | Biotech Hunter